rupintrivir profile

rupintrivir: a rhinovirus 3C protease inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6440352
CHEMBL ID	20210
SCHEMBL ID	141565
MeSH ID	M0304505

Synonym
ag-7088
D05776
rupintrivir (usan/inn)
2-pentenoicacid,4-[[(2r,5s)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[[(5-methyl-3-isoxazolyl)carbonyl]amino]-1,4-dioxoheptyl]amino]-5-[(3s)-2-oxo-3-pyrrolidinyl]-, ethyl ester, (2e,4s)-
223537-30-2
ethyl (e,4s)-4-[[(2r,5s)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methylisoxazole-3-carbonyl)amino]-4-oxo-heptanoyl]amino]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate
ag7088
rupintrivir
ruprintrivir
ethyl (2e,4s)-4-[((2r,5s)-2-(4-fluorobenzyl)-6-methyl-5-{[(5-methylisoxazol-3-yl)carbonyl]amino}-4-oxoheptanoyl)amino]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate
ethyl (2e,4s)-4-[(2r,5s)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazol-3-yl)formamido]-4-oxoheptanamido]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate
chembl20210 ,
bdbm11243
ethyl (e,4s)-4-[[(2r,5s)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-4-oxoheptanoyl]amino]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate
2-pentenoic acid, 4-(((2r,5s)-2-((4-fluorophenyl)methyl)-6-methyl-5-(((5-methyl-3-isoxazolyl)carbonyl)amino)-1,4-dioxoheptyl)amino)-5-((3s)-2-oxo-3-pyrrolidinyl)-, ethyl ester, (2e,4s)-
rge5k1q5qw ,
ethyl-3-((5'-methylisoxazole-3'-carbonyl)-valpsi(coch2)phe(4-f)-(pyrrol-ala))propenoate
rupintrivir [usan:inn]
ethyl (2e,4s)-4-(((2r,5s)-2-(4-fluorobenzyl)-6-methyl-5-(((5-methylisoxazol-3-yl)carbonyl)amino)-4-oxoheptanoyl)amino)-5-((3s)-2-oxopyrrolidin-3-yl)pent-2-enoate
ag 7088
(trans-(4s,2'r,5's,3''s)-4-(2'-4-(4-fluorobenzyl)-6'-methyl-5'-((5''-methylisoxazole)-3''-carbonylamino)-4-oxoheptanoylamino))-5-(2''-oxopyrrolidin-3'''-yl)pent-2-enoic acid ethyl ester
unii-rge5k1q5qw
2-pentenoic acid, 4-(((2r,5s)-2-((4-fluorophenyl)methyl)-6-methyl-5-(((5-methyl-3-isoxazolyl)carbonyl)amino)-1,4-dioxoheptyl)amino)-5-((3s)-2-oxo-3-pyrrolidinyl)-, ethylester, (2e,4s)-
rupintrivir-d4
rupintrivir [inn]
rupintrivir [usan]
ethyl (2e,4s)-4-[[(2r,5s)-2-(4-fluorobenzyl)-6-methyl-5-[[(5-methylisoxazol-3-yl)carbonyl]amino]-4-oxoheptanoyl]amino]-5-[(3s)-2-oxopyrrolidin-3-yl]pent-2-enoate
DB05102
AKOS022183380
SCHEMBL141565
(e)-(s)-4-{(2r,5s)-2-(4-fluoro-benzyl)-6-methyl-5-[(5-methyl-isoxazole-3-carbonyl)-amino]-4-oxo-heptanoylamino}-5-((s)-2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester
ethyl (s,e)-4-((2r,5s)-2-(4-fluorobenzyl)-6-methyl-5-(5-methylisoxazole-3-carboxamido)-4-oxoheptanamido)-5-((s)-2-oxopyrrolidin-3-yl)pent-2-enoate
HY-106161
ethyl (2e,4s)-4-[[(2r,5s)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[[(5-methyl-3-isoxazolyl)carbonyl]amino]-1,4-dioxoheptyl]amino]-5-[(3s)-2-oxo-3-pyrrolidinyl]-2-pentenoate
Q27095569
(s,e)-ethyl 4-((2r,5s)-2-(4-fluorobenzyl)-6-methyl-5-(5-methylisoxazole-3-carboxamido)-4-oxoheptanamido)-5-((s)-2-oxopyrrolidin-3-yl)pent-2-enoate
CS-0025036
AT25670
MS-30602
(s,e)-ethyl4-((2r,5s)-2-(4-fluorobenzyl)-6-methyl-5-(5-methylisoxazole-3-carboxamido)-4-oxoheptanamido)-5-((s)-2-oxopyrrolidin-3-yl)pent-2-enoate
NCGC00346443-02
223537-30-2 (unlabeled)
DTXSID201028116

Excerpt	Reference	Relevance
"Rupintrivir (AG7088) is a compound originally designed for Rhinovirus 3C protease."	( Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Chen, L; Hu, Y; Qin, B; Song, Z; Yuan, Z; Zhang, X, 2013)	2.55

Excerpt	Reference	Relevance
" Intranasal ruprintrivir, administered as single doses of 4 and 8 mg or every 3 h, six times per day, for 7 days was safe and well tolerated."	( Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Gersten, M; Hsyu, PH; Kerr, BM; Penning, CA; Pithavala, YK, 2002)	0.31

Excerpt	Relevance	Reference
" Concentrations of AG7185 observed during multiple dosing were higher than those observed after the first dose but were no more than predicted from the single-dose study."	( Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Gersten, M; Hsyu, PH; Kerr, BM; Penning, CA; Pithavala, YK, 2002)	0.31
" Ruprintrivir prophylaxis reduced the proportion of subjects with positive viral cultures (for 5x/day dosing groups, 44% for ruprintrivir treatment group versus 70% for placebo treatment group [P=0."	( Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Chi-Burris, K; Gersten, M; Gwaltney, JM; Hayden, FG; Hsyu, P; Patick, AK; Smith, GJ; Turner, RB; Zalman, LS, 2003)	0.32

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	8.4866	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	4.7724	0.0123	8.9648	39.8107	AID1645842
Interferon beta	Homo sapiens (human)	Potency	4.7724	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	4.7724	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	4.7724	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	4.7724	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Betacoronavirus England 1	IC50 (µMol)	410.0000	0.0300	2.7283	9.5100	AID1804127
Spike glycoprotein	Betacoronavirus England 1	Ki	10.0000	0.0075	0.0075	0.0075	AID1804127
Replicase polyprotein 1ab	Betacoronavirus England 1	IC50 (µMol)	280.0000	0.0040	3.4388	9.5100	AID1804127; AID1805532
Replicase polyprotein 1ab	Betacoronavirus England 1	Ki	10.0000	0.0075	1.1337	2.2600	AID1804127
Transmembrane protease serine 2	Homo sapiens (human)	IC50 (µMol)	410.0000	0.0180	2.6198	9.5100	AID1804127
Transmembrane protease serine 2	Homo sapiens (human)	Ki	10.0000	0.0042	0.1288	0.6210	AID1804127
Procathepsin L	Homo sapiens (human)	IC50 (µMol)	410.0000	0.0002	1.6661	9.5100	AID1804127
Procathepsin L	Homo sapiens (human)	Ki	10.0000	0.0000	1.1013	9.3000	AID1804127
Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	410.0000	0.0300	2.2971	9.5100	AID1804127
Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus	Ki	10.0000	0.0075	3.2392	9.1100	AID1804127
Replicase polyprotein 1ab	Human coronavirus 229E	IC50 (µMol)	410.0000	0.0300	2.1441	9.5100	AID1804127
Replicase polyprotein 1ab	Human coronavirus 229E	Ki	10.0000	0.0000	0.7332	9.1100	AID1804127
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	235.0000	0.0040	2.9266	9.9600	AID1796657; AID1804127; AID1805532
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	Ki	10.0000	0.0075	3.0083	9.1100	AID1804127
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50 (µMol)	215.0000	0.0002	2.4585	9.9600	AID1804127; AID1805532; AID1845236
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	Ki	10.0000	0.0000	1.6307	9.0000	AID1804127
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	410.0000	0.0300	2.7731	9.5100	AID1804127
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Ki	10.0000	0.0075	0.0075	0.0075	AID1804127
Genome polyprotein	Human rhinovirus sp.	IC50 (µMol)	0.0230	0.0005	2.9838	8.2000	AID161384
Angiotensin-converting enzyme 2	Homo sapiens (human)	IC50 (µMol)	410.0000	0.0004	2.2079	10.0000	AID1804127
Angiotensin-converting enzyme 2	Homo sapiens (human)	Ki	10.0000	0.0075	0.0075	0.0075	AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Genome polyprotein	Human rhinovirus sp.	EC50 (µMol)	0.0050	0.0050	0.0932	0.4400	AID163830; AID163834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Genome polyprotein	Human rhinovirus sp.	EC90 (µMol)	0.0478	0.0200	0.0478	0.1000	AID163966; AID163967; AID163969; AID163971
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
viral translation	Transmembrane protease serine 2	Homo sapiens (human)
proteolysis	Transmembrane protease serine 2	Homo sapiens (human)
protein autoprocessing	Transmembrane protease serine 2	Homo sapiens (human)
positive regulation of viral entry into host cell	Transmembrane protease serine 2	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	Procathepsin L	Homo sapiens (human)
proteolysis	Procathepsin L	Homo sapiens (human)
protein autoprocessing	Procathepsin L	Homo sapiens (human)
fusion of virus membrane with host plasma membrane	Procathepsin L	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Procathepsin L	Homo sapiens (human)
antigen processing and presentation	Procathepsin L	Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class II	Procathepsin L	Homo sapiens (human)
collagen catabolic process	Procathepsin L	Homo sapiens (human)
zymogen activation	Procathepsin L	Homo sapiens (human)
enkephalin processing	Procathepsin L	Homo sapiens (human)
fusion of virus membrane with host endosome membrane	Procathepsin L	Homo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitment	Procathepsin L	Homo sapiens (human)
symbiont entry into host cell	Procathepsin L	Homo sapiens (human)
antigen processing and presentation of peptide antigen	Procathepsin L	Homo sapiens (human)
proteolysis involved in protein catabolic process	Procathepsin L	Homo sapiens (human)
elastin catabolic process	Procathepsin L	Homo sapiens (human)
macrophage apoptotic process	Procathepsin L	Homo sapiens (human)
cellular response to thyroid hormone stimulus	Procathepsin L	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Procathepsin L	Homo sapiens (human)
positive regulation of peptidase activity	Procathepsin L	Homo sapiens (human)
immune response	Procathepsin L	Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of signaling receptor activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
symbiont entry into host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cytokine production	Angiotensin-converting enzyme 2	Homo sapiens (human)
angiotensin maturation	Angiotensin-converting enzyme 2	Homo sapiens (human)
angiotensin-mediated drinking behavior	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Angiotensin-converting enzyme 2	Homo sapiens (human)
tryptophan transport	Angiotensin-converting enzyme 2	Homo sapiens (human)
viral life cycle	Angiotensin-converting enzyme 2	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of vasoconstriction	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of transmembrane transporter activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cell population proliferation	Angiotensin-converting enzyme 2	Homo sapiens (human)
symbiont entry into host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
receptor-mediated virion attachment to host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
negative regulation of smooth muscle cell proliferation	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of inflammatory response	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of amino acid transport	Angiotensin-converting enzyme 2	Homo sapiens (human)
maternal process involved in female pregnancy	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane fusion	Angiotensin-converting enzyme 2	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Angiotensin-converting enzyme 2	Homo sapiens (human)
blood vessel diameter maintenance	Angiotensin-converting enzyme 2	Homo sapiens (human)
entry receptor-mediated virion attachment to host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of gap junction assembly	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cardiac conduction	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of L-proline import across plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
serine-type endopeptidase activity	Transmembrane protease serine 2	Homo sapiens (human)
protein binding	Transmembrane protease serine 2	Homo sapiens (human)
serine-type peptidase activity	Transmembrane protease serine 2	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
fibronectin binding	Procathepsin L	Homo sapiens (human)
cysteine-type endopeptidase activity	Procathepsin L	Homo sapiens (human)
protein binding	Procathepsin L	Homo sapiens (human)
collagen binding	Procathepsin L	Homo sapiens (human)
cysteine-type peptidase activity	Procathepsin L	Homo sapiens (human)
histone binding	Procathepsin L	Homo sapiens (human)
proteoglycan binding	Procathepsin L	Homo sapiens (human)
serpin family protein binding	Procathepsin L	Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic process	Procathepsin L	Homo sapiens (human)
RNA-dependent RNA polymerase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
virus receptor activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
endopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
carboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallocarboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
peptidyl-dipeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
zinc ion binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
identical protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Transmembrane protease serine 2	Homo sapiens (human)
nucleoplasm	Transmembrane protease serine 2	Homo sapiens (human)
plasma membrane	Transmembrane protease serine 2	Homo sapiens (human)
extracellular exosome	Transmembrane protease serine 2	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular region	Procathepsin L	Homo sapiens (human)
extracellular space	Procathepsin L	Homo sapiens (human)
nucleus	Procathepsin L	Homo sapiens (human)
lysosome	Procathepsin L	Homo sapiens (human)
multivesicular body	Procathepsin L	Homo sapiens (human)
Golgi apparatus	Procathepsin L	Homo sapiens (human)
plasma membrane	Procathepsin L	Homo sapiens (human)
apical plasma membrane	Procathepsin L	Homo sapiens (human)
endolysosome lumen	Procathepsin L	Homo sapiens (human)
chromaffin granule	Procathepsin L	Homo sapiens (human)
lysosomal lumen	Procathepsin L	Homo sapiens (human)
intracellular membrane-bounded organelle	Procathepsin L	Homo sapiens (human)
collagen-containing extracellular matrix	Procathepsin L	Homo sapiens (human)
extracellular exosome	Procathepsin L	Homo sapiens (human)
endocytic vesicle lumen	Procathepsin L	Homo sapiens (human)
extracellular space	Procathepsin L	Homo sapiens (human)
lysosome	Procathepsin L	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular region	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
endoplasmic reticulum lumen	Angiotensin-converting enzyme 2	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
cilium	Angiotensin-converting enzyme 2	Homo sapiens (human)
cell surface	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
apical plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
endocytic vesicle membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
brush border membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane raft	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular exosome	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (189)

Assay ID	Title	Year	Journal	Article
AID1306403	Antiviral activity against human rhinovirus 2 assessed as reduction in viral infection in human HeLa H1 cells after 2 to 5 days by XTT reduction assay	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.
AID542597	Antiviral activity against Human enterovirus Echo9 infected in human HeLa-G3CwtR cells after 36 to 48 hrs by FRET assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID24323	half life towards biological agent (dog plasma)	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423669	Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, N132S, Y139Y/H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 12 passages for 72 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423687	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 2 passages for 10 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID24326	half life towards biological agent (rat plasma)	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423892	Ratio of EC50 for HRV Hanks infected in human H1-HeLa cells after 1 passage for 7 days to EC50 for wild type HRV Hanks infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID163986	Inhibition of rhinovirus 3C protease.	2000	Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3	Protease inhibitors: current status and future prospects.
AID542785	Antiviral activity against Human enterovirus CVB1 infected in Vero cells after 4 to 7 days by plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID423888	Antiviral activity against HRV39 with 3C protease S105S/T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 33 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423686	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 1 passage for 6 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423662	Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 22 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1537190	Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by SRB assay	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Lignan Dimers from Forsythia viridissima Roots and Their Antiviral Effects.
AID423656	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 12 passages for 72 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID673872	Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
AID163969	The EC90 was calculated as the concentration of drug that increased the percentage of formazan production in drug treated, virus infected cells to 50% of that produced by drug free uninfected cells on human rhinovirus-10.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423877	Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 3 passages for 14 days to EC50 for wild type HRV39 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID673879	Ratio of EC50 for major receptor-resistant Human rhinovirus B to EC50 for minor receptor-resistant Human rhinovirus A	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
AID24324	half life towards biological agent (human plasma)	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID1266411	Inhibition of Norovirus 3C-like protease by FRET assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Recent Advances in the Discovery of Norovirus Therapeutics.
AID423873	Ratio of EC50 for HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells after 6 passages for 37 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423704	Antiviral activity against HRV2 with 3C protease A103A/V, N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 8 passages for 52 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID323991	Inhibition of HRV14 3C protease in presence of dithiothreitol	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	New anti-viral drugs for the treatment of the common cold.
AID423882	Antiviral activity against wild type HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423905	Antiviral activity against 0.02 MOI HRV14 infected in human H1-HeLa cells assessed as cell killing after 5 passages for 22 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423899	Antiviral activity against HRV Hanks infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 2 passages for 17 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423696	Antiviral activity against wild type HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423895	Ratio of EC50 for HRV Hanks infected in human H1-HeLa cells after 6 passage for 40 days to EC50 for wild type HRV Hanks infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423702	Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 37 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423675	Ratio of EC50 for HRV14 with 3C protease with A121A/V, T129A, T131A, N132S, Y139Y/H, T143P mutation infected in human H1-HeLa cells after 12 passages for 72 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423681	Ratio of EC50 for HRV14 with 3C protease T129A mutation infected in human H1-HeLa cells to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID673875	Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
AID423692	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 7 passages for 45 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1845236	Inhibition of SARS-CoV-2 MPro	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID423900	Antiviral activity against HRV Hanks infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 35 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423655	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 11 passages for 65 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423663	Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 27 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423673	Ratio of EC50 for HRV14 with 3C protease with T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells after 10 passages for 55 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423906	Antiviral activity against HRV14 with capsid protein VP1 V191L mutation relative to wild type HRV14	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1306405	Antiviral activity against human rhinovirus 17 assessed as reduction in viral infection in human HeLa H1 cells after 2 to 5 days by XTT reduction assay	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.
AID1305673	AUC in mouse at 3 mg/kg, iv	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis, and biological evaluation of anti-EV71 agents.
AID423898	Antiviral activity against HRV Hanks infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 1 passage for 7 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423670	Ratio of EC50 for HRV14 with 3C protease T129T/A, T131T/A, T143P/S mutation infected in human H1-HeLa cells after 3 passages for 14 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID228287	The 50% cytotoxic concentration was calculated as the concentration of the drug that decreased the percentage of formazan produced in drug-treated,uninfected cells to 50% of that produced in drug free uninfected cells on serotype 14.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423486	Ratio of EC50 for HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells after 3 passages for 24 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423695	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 10 passages for 66 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423889	Antiviral activity against HRV39 with 3C protease S105T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 50 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID542594	Antiviral activity against Human enterovirus CVB1 infected in human HeLa-G3CwtR cells after 36 to 48 hrs by FRET assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID324001	Antiviral activity against HRV2 in HeLa cells	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	New anti-viral drugs for the treatment of the common cold.
AID256497	Cytostatic concentration against WI-38 cells	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein.
AID423658	Antiviral activity against HRV14 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 1 passage for 6 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423677	Antiviral activity against HRV14 with 3C protease T131A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID542596	Antiviral activity against Human enterovirus CVB4 infected in human HeLa-G3CwtR cells after 36 to 48 hrs by FRET assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID423657	Antiviral activity against wild type HRV14 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID542595	Antiviral activity against Human enterovirus CVB2 infected in human HeLa-G3CwtR cells after 36 to 48 hrs by FRET assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID1894258	Antiviral activity against Human rhinovirus 14 infected in H1-HeLa cells assessed as reduction in viral infection measured after 5 days by XTT dye reduction method	2021	Bioorganic & medicinal chemistry letters, 04-15, Volume: 38	Pyridones in drug discovery: Recent advances.
AID423650	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 6 passages for 27 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1305679	Metabolic stability in mouse plasma assessed as compound remaining after 2 hrs	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis, and biological evaluation of anti-EV71 agents.
AID1537188	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3 infected in African green monkey Vero cells	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Lignan Dimers from Forsythia viridissima Roots and Their Antiviral Effects.
AID423699	Antiviral activity against HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 17 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423893	Ratio of EC50 for HRV Hanks infected in human H1-HeLa cells after 2 passage for 17 days to EC50 for wild type HRV Hanks infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID24321	half life towards biological agent (chymotrypsin)	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423894	Ratio of EC50 for HRV Hanks infected in human H1-HeLa cells after 3 passage for 35 days to EC50 for wild type HRV Hanks infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID46550	% activity against calpain 1 remaining after 10-15 min at 10 uM	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423880	Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 6 passages for 33 days to EC50 for wild type HRV39 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423879	Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 5 passages for 29 days to EC50 for wild type HRV39 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423661	Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 17 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423902	Antiviral activity against HRV Hanks with 3C protease T130A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 59 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423672	Ratio of EC50 for HRV14 with 3C protease with T129A, T131T/A, T143P mutation infected in human H1-HeLa cells after 5 passages for 22 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID542794	Antiviral activity against Human enterovirus Echo9 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID67162	% activity against elastase remaining after 10-15 min at 10 uM	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID89492	Enzyme inhibition against Human Rhinovirus 3C protease was determined	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.
AID1567010	Antiviral activity against Enterovirus A71 695F infected in human muscular rhabdomyosarcoma cells assessed as reduction in virus-induced cell death incubated for 3 days by CCK-8 assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.
AID673878	Ratio of EC50 for antiviral-resistant Human rhinovirus B to EC50 for antiviral-resistant Human rhinovirus A	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
AID423887	Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 29 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423901	Antiviral activity against HRV Hanks with 3C protease T130A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 40 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423682	Ratio of EC50 for HRV14 with 3C protease T131A mutation infected in human H1-HeLa cells to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423683	Ratio of EC50 for HRV14 with 3C protease Y139H mutation infected in human H1-HeLa cells to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID79757	Anti viral activity against human rhinovirus (HRV) in H1HeLa cells	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.
AID1414464	Covalent binding affinity to EV71 3C protease expressed in Escherichia coli BL21(DE3) at 2 mg/ml incubated for 2 to 3 hrs and measured after trypsin digestion by by LC-MS/MS analysis	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	4-Iminooxazolidin-2-one as a Bioisostere of the Cyanohydrin Moiety: Inhibitors of Enterovirus 71 3C Protease.
AID423691	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 6 passages for 37 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID542793	Antiviral activity against Human enterovirus CVB4 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID50450	Inhibition of cathepsin B by the compound was measured as % activity of thrombin remaining after 10-15 min at 10 uM	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID673873	Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
AID215013	Inhibition of trypsin by the compound was measured as % activity of thrombin remaining after 10-15 min at 10 uM	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID542790	Antiviral activity against Human enterovirus CVA16 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID542787	Antiviral activity against Human enterovirus CVB4 infected in Vero cells after 4 to 7 days by plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID1537186	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 2 days by SRB staining based microscopic method	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Lignan Dimers from Forsythia viridissima Roots and Their Antiviral Effects.
AID423684	Ratio of EC50 for HRV14 with 3C protease T143P mutation infected in human H1-HeLa cells to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423679	Antiviral activity against HRV14 with 3C protease T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423904	Antiviral activity against 0.02 MOI wild type HRV14 infected in human H1-HeLa cells assessed as cell killing after 3 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423874	Ratio of EC50 for HRV2 with 3C protease E3E/G, A103A/V, N165T mutation infected in human H1-HeLa cells after 9 passages for 62 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423660	Antiviral activity against HRV14 with 3C protease T129T/A, T131T/A, T143P/S mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 14 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID673877	Ratio of EC50 for Human rhinovirus B to EC50 for Human rhinovirus A	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
AID1338299	Antiviral activity against Coxsackievirus A16 assessed as reduction in viral replication after 72 hrs by CellTiter-glo luminescent cell viability assay	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening.
AID542802	Antiviral activity against Human enterovirus EV71 infected in Vero cells after 4 to 7 days by plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID423703	Antiviral activity against HRV2 with 3C protease A103A/V, N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 7 passages for 45 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423876	Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 2 passages for 12 days to EC50 for wild type HRV39 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID542791	Antiviral activity against Human enterovirus CVB1 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID1306404	Antiviral activity against human rhinovirus 16 assessed as reduction in viral infection in human HeLa H1 cells after 2 to 5 days by XTT reduction assay	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.
AID423652	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 8 passages for 40 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423487	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 1 passage for 6 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1567034	Antiviral activity against Enterovirus A71 EV71/Shenzhen/120F1/09 infected in human muscular rhabdomyosarcoma cells assessed as reduction in virus-induced cell death incubated for 3 days by CCK-8 assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.
AID542789	Antiviral activity against Human enterovirus EV71 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID423676	Antiviral activity against HRV14 with 3C protease T129A mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423897	Antiviral activity against wild type HRV Hanks infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID542592	Antiviral activity against Human enterovirus EV71 infected in human HeLa-G3CwtR cells after 36 to 48 hrs by FRET assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID423649	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 5 passages for 22 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1265714	Antiviral activity against EV71	2015	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24	Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition.
AID673874	Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
AID1445121	Antiviral activity against Human rhinovirus B14 infected in H1HeLa cells assessed as decrease in viral dsRNA at 6 times EC50 treated every 1 hr for 6 hrs after infection by DAPI staining based immunofluorescence assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID423698	Antiviral activity against HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 2 passages for 10 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423664	Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 7 passages for 33 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423690	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 5 passages for 30 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423872	Ratio of EC50 for HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells after 5 passages for 30 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID342531	Antiviral activity against Human echovirus 6	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents.
AID342532	Antiviral activity against Human echovirus 9	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents.
AID323998	Antiviral activity against HRV14	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	New anti-viral drugs for the treatment of the common cold.
AID423870	Antiviral activity against HRV2 with 3C protease E3E/G, A103A/V, N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 10 passages for 66 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID79756	Cytotoxicity against uninfected H1HeLa cells	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.
AID423907	Antiviral activity against Coxsackievirus B3 (strain Nancy) with capsid protein VP1 I92M/L mutation relative to wild type Coxsackievirus B3 (strain Nancy)	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID542786	Antiviral activity against Human enterovirus CVB2 infected in Vero cells after 4 to 7 days by plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID423648	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 4 passages for 17 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID542788	Antiviral activity against Human enterovirus Echo9 infected in Vero cells after 4 to 7 days by plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID163987	Irreversible inhibition of human rhinovirus 3C protease	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423869	Antiviral activity against HRV2 with 3C protease E3E/G, A103A/V, N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 62 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423685	Ratio of EC50 for HRV14 with 3C protease T129A, T131A, Y139H, T143P mutation infected in human H1-HeLa cells to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423694	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 9 passages for 62 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423654	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 10 passages for 55 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423674	Ratio of EC50 for HRV14 with 3C protease with A121A/V, T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells after 11 passages for 65 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423668	Antiviral activity against HRV14 with 3C protease A121A/V, T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 11 passages for 65 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1338297	Inhibition of recombinant N-terminal 6His-tagged EV71 3C protease expressed in Escherichia coli Rosetta using substrate Dabcyl-RTATVQGPSLDFE-Edans at 50 uM after 30 mins by fluorescence assay	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening.
AID423891	Ratio of EC50 for HRV39 with 3C protease S105S/T, N130K, L136F mutation infected in human H1-HeLa cells after 9 passages for 50 days to EC50 for wild type HRV39 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423883	Antiviral activity against HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 1 passage for 7 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID17088	Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.
AID423488	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 2 passages for 11 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423886	Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 24 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423659	Antiviral activity against HRV14 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 2 passages for 11 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423884	Antiviral activity against HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 2 passages for 12 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID673871	Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
AID423697	Antiviral activity against HRV2 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 1 passage for 6 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423890	Ratio of EC50 for HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells after 5 passages for 29 days to EC50 for wild type HRV39 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID163971	The EC90 was calculated as the concentration of drug that increased the percentage of formazan production in drug treated, virus infected cells to 50% of that produced by drug free uninfected cells on human rhinovirus-14.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423896	Ratio of EC50 for HRV Hanks infected in human H1-HeLa cells after 9 passage for 59 days to EC50 for wild type HRV Hanks infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID24322	half life towards biological agent (dithiothreitol 5 mM)	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423693	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 8 passages for 52 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1265720	Inhibition of EV71 protease 3C using Dabcyl-KTSAVLQSGFRKME-Edans as substrate by fluorescence analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Cyanohydrin as an Anchoring Group for Potent and Selective Inhibitors of Enterovirus 71 3C Protease.
AID1445118	Antiviral activity against Human rhinovirus A16 infected in human H1HeLa cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID423666	Antiviral activity against HRV14 with 3C protease T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 48 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423489	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 3 passages for 14 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID211384	Inhibition of thrombin by the compound was measured as % activity of thrombin remaining after 10-15 min at 10 uM	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423680	Antiviral activity against HRV14 with 3C protease T129A, T131A, Y139H, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1567009	Inhibition of Enterovirus 71 E2004104-TW-CDC protease 3C (1549 to 1731 residues) expressed in Escherichia coli BL21(DE3) cells using Dacyl-KRTATVQGPSLDFE-Edans as substrate by fluorescence method	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.
AID423885	Antiviral activity against HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 14 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1537189	Antiviral activity against Human rhinovirus 1B infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect after 2 days by SRB staining based microscopic method	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Lignan Dimers from Forsythia viridissima Roots and Their Antiviral Effects.
AID161384	Reversible inhibitory activity against Protease	2004	Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14	Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase.
AID542593	Antiviral activity against Human enterovirus CVA16 infected in human HeLa-G3CwtR cells after 36 to 48 hrs by FRET assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID423903	Ratio of EC50 for HRV Hanks with 3C protease T130A mutation infected in human H1-HeLa cells after 6 passages for 40 days to EC50 for wild type HRV Hanks infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1305678	Antiviral activity against Enterovirus 71/Shenzhen/120F1/09 infected in human RD cells assessed as reduction in virus induced cell death after 72 hrs by CCK-8 assay	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis, and biological evaluation of anti-EV71 agents.
AID673876	Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4	An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
AID163830	Effective concentration against human rhinovirus 3C protease.	2000	Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3	Protease inhibitors: current status and future prospects.
AID52599	Inhibition of Chymotrypsinogen by the compound was measured as % activity of thrombin remaining after 10-15 min at 10 uM	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID542784	Antiviral activity against Human enterovirus CVA16 infected in Vero cells after 4 to 7 days by plaque reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID423700	Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 24 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423651	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 7 passages for 33 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1537187	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 2 days by SRB assay	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Lignan Dimers from Forsythia viridissima Roots and Their Antiviral Effects.
AID423665	Antiviral activity against HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 8 passages for 40 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1338293	Inhibition of recombinant N-terminal 6His-tagged EV71 3C protease expressed in Escherichia coli Rosetta using substrate Dabcyl-RTATVQGPSLDFE-Edans preincubated for 30 mins followed by substrate addition	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening.
AID163834	Increased percentage of formazan production in drug treated virus infected cells to equal 50% control drug free uninfected cells on serotype 14	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423701	Antiviral activity against HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 30 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423871	Ratio of EC50 for HRV2 with 3C protease N165T mutation infected in human H1-HeLa cells after 4 passages for 24 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID24325	half life towards biological agent (peptidase)	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID423667	Antiviral activity against HRV14 with 3C protease T129A, T131A, T143P, Y139Y/H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 10 passages for 55 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423689	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 4 passages for 24 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423881	Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 9 passages for 50 days to EC50 for wild type HRV39 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423875	Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 1 passage for 7 days to EC50 for wild type HRV39 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID17089	Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.
AID423878	Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 4 passages for 24 days to EC50 for wild type HRV39 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423688	Ratio of EC50 for HRV2 infected in human H1-HeLa cells after 3 passages for 17 days to EC50 for wild type HRV2 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423653	Ratio of EC50 for HRV14 infected in human H1-HeLa cells after 9 passages for 48 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID423671	Ratio of EC50 for HRV14 with 3C protease T129A, T131T/A, T143P mutation infected in human H1-HeLa cells after 4 passages for 17 days to EC50 for wild type HRV14 infected in human H1-HeLa cells	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID1894257	Irreversible inhibition of human rhinovirus 14 3C protease assessed as Kobs/[I] by FRET assay	2021	Bioorganic & medicinal chemistry letters, 04-15, Volume: 38	Pyridones in drug discovery: Recent advances.
AID542792	Antiviral activity against Human enterovirus CVB2 infected in human HeLa cells after 2 to 4 days by formazan dye reduction assay	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.
AID423678	Antiviral activity against HRV14 with 3C protease Y139H mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
AID163967	The EC90 was calculated as the concentration of drug that increased the percentage of formazan production in drug treated, virus infected cells to 50% of that produced by drug free uninfected cells on human rhinovirus 2.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID163966	The EC90 was calculated as the concentration of drug that increased the percentage of formazan production in drug treated, virus infected cells to 50% of that produced by drug free uninfected cells on human rhinovirus 1A.	1999	Journal of medicinal chemistry, Apr-08, Volume: 42, Issue:7	Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
AID1796657	SARS-CoV 3CL Protease Inhibition Assay from Article 10.1016/j.bmc.2005.05.065: \\Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.\\	2005	Bioorganic & medicinal chemistry, Sep-01, Volume: 13, Issue:17	Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.
AID1804127	No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\	2021	Medicinal research reviews, 01, Volume: 41, Issue:1	The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1805532	Various Assay from Article 10.1002/cmdc.202100576: \\A patent review on SARS coronavirus main protease (3CLpro) inhibitors.\\	2022	ChemMedChem, 01-05, Volume: 17, Issue:1	A Patent Review on SARS Coronavirus Main Protease (3CL
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (4.41)	18.2507
2000's	21 (30.88)	29.6817
2010's	34 (50.00)	24.3611
2020's	10 (14.71)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (2.90%)	5.53%
Reviews	13 (18.84%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	54 (78.26%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
taxifolin [no description available]	3.51	1	0	3'-hydroxyflavanones; 4'-hydroxyflavanones; dihydroflavonols; pentahydroxyflavanone; secondary alpha-hydroxy ketone
sch-48973 [no description available]	2.15	1	0
pleconaril WIN 63843: structure given in first source	5.45	7	0
amodiaquine Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.	3.41	1	0	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	3.41	1	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
camostat camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.	4.33	2	0	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor
carmofur [no description available]	4.33	2	0	organohalogen compound; pyrimidines
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	3.41	1	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	3.41	1	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	3.41	1	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
disulfiram [no description available]	4.33	2	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	4.33	2	0	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	3.41	1	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
fluphenazine [no description available]	3.41	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
fluspirilene Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.	3.41	1	0	diarylmethane
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	3.41	1	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	3.41	1	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	3.1	1	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
loperamide Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	3.41	1	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	3.1	1	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
mefloquine hydrochloride [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.	3.41	1	0	organofluorine compound; piperidines; quinolines; secondary alcohol
fidexaban Fidexaban: structure in first source	3.1	1	0
nafamostat nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic	3.1	1	0	benzoic acids; guanidines
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	3.41	1	0	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	3.41	1	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
imatinib [no description available]	3.41	1	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.13	1	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
thiethylperazine Thiethylperazine: A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457). thiethylperazine : A member of the class of phenothiazines that is perazine substituted by a ethylsulfanyl group at position 2.	3.41	1	0	N-methylpiperazine; phenothiazines	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
triflupromazine Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.. triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.	3.41	1	0	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	2	1	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	3.13	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	10.64	46	2	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cytidine [no description available]	2.1	1	0	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	3.41	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
tubercidin Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.	2.1	1	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	10.64	46	2	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
chlorphenoxamine chlorphenoxamine: minor descriptor (66-84); on-line & Index Medicus search ETHYLAMINES (66-84); RN given refers to parent cpd	3.41	1	0	diarylmethane	anticoronaviral agent
divinyl sulfone divinyl sulfone: cross-linking reagent for agarose gels. divinyl sulfone : A sulfone compound having two S-vinyl substituents.	3.13	1	0	sulfone	cross-linking reagent
triparanol Triparanol: Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.	3.41	1	0	stilbenoid	anticoronaviral agent
suramin sodium suramin sodium : An organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness.	3.21	1	0	organic sodium salt	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
potassium cyanide [no description available]	2.11	1	0	cyanide salt; one-carbon compound; potassium salt	EC 1.15.1.1 (superoxide dismutase) inhibitor; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; neurotoxin
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	10.64	46	2	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	8.34	8	2	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.52	2	0	diazine; pyrazines	Daphnia magna metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	3.41	1	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
acetophenazine acetophenazine: major descriptor (73-85); minor descriptor (64-72); on-line search PHENOTHIAZINES (64-85); Index Medicus search PHENOTHIAZINES (64-72); ACETOPHENAZINE (73-85); RN given refers to parent cpd. acetophenazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2.	3.41	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; phenothiazines	phenothiazine antipsychotic drug
ribavirin Rebetron: Rebetron is tradename	3.41	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	3.1	1	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
quinapril Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.	3.1	1	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	2.13	1	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	3.41	1	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.1	1	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	4.08	2	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
baicalin [no description available]	3.41	1	0	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
amprenavir [no description available]	3.1	1	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
inogatran inogatran: a direct low molecular weight thrombin inhibitor	3.1	1	0
pirodavir pirodavir: antipicornavirus agent; structure given in first source	2.78	3	0
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	3.41	1	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
leupeptin [no description available]	2.04	1	0	aldehyde; tripeptide	bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor
carbobenzoxyvalylphenylalanine aldehyde Z-Val-Phe-H : A dipeptide resulting from the formal condensation of the carboxy group of N-benzyloxycarbonyl-L-valine with the amino group of L-phenylalanine aldehyde. It is a potent cell-permeable inhibitor of calpain I and II, and is also a gamma-secretase inhibitor.	3.41	1	0	aldehyde; carbamate ester; dipeptide	antileishmanial agent; apoptosis inhibitor; EC 3.4.22.52 (calpain-1) inhibitor; EC 3.4.22.53 (calpain-2) inhibitor; EC 3.4.23.46 (memapsin 2) inhibitor
palinavir [no description available]	3.1	1	0	N-acyl-amino acid
calpeptin [no description available]	4.07	2	0	amino acid amide
moexipril [no description available]	3.1	1	0	peptide
zofenopril zofenopril: structure given in first source; SQ 26900 refers to K salt & SQ 26991 to Ca salt. zofenopril : A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-3-(benzoylsulfanyl)-2-methylpropanoyl group. A prodrug for zofenoprilat.	3.1	1	0	aryl sulfide; L-proline derivative; N-acyl-L-amino acid; thioester	anticonvulsant; apoptosis inhibitor; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug; vasodilator agent
mci 9038 [no description available]	3.1	1	0	peptide
lopinavir [no description available]	4.73	3	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
sivelestat sivelestat: inhibitor of neutrophil elastase; structure given in first source	3.1	1	0	N-acylglycine; pivalate ester
sepimostate mesilate sepimostate mesilate: used in therapy of pancreatitis; structure given in first source	3.1	1	0
matairesinol matairesinol: lignan that is a central precursor in plants in the biosynthesis of numerous lignans (coordinate with specific); RN refers to (3R-trans)-isomer. (-)-matairesinol : A lignan that is gamma-butyrolactone in which the 3 and 4 positions are substituted by 4-hydroxy-3-methoxybenzyl groups (the 3R,4R-diastereomer).	2.21	1	0	gamma-lactone; lignan; polyphenol	angiogenesis inhibitor; anti-asthmatic agent; phytoestrogen; plant metabolite
l 658758 L 658758: structure & chemical name given in UD	3.1	1	0
dx 9065 [no description available]	3.1	1	0
acetylphenylalanyl-prolyl-boroarginine Ac-(D)Phe-Pro-boroArg-OH : A C-terminal boronic acid petide that is N-acetyl-D-phenylalanyl-L-prolyl-L-arginine in which the C-termnal carboxy group has been replaced by a borono (-B(OH)2) group. A thrombin (Factor IIa) inhibitor, thereby acting as an anticoagulant.. DuP-714 : A hydrochloride resulting from the formal reaction of equimolar amounts of Ac-(D)Phe-Pro-boroArg-OH and hydrogen chloride. A thrombin (Factor IIa) inhibitor, thereby acting as an anticoagulant.	3.1	1	0	acetamides; C-terminal boronic acid peptide; guanidines	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)	3.13	1	0	leucine derivative
e 64 E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)	3.1	1	0	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor
benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone: inhibits cathepsins B and L	3.1	1	0	carboxylic ester; diazo compound; L-phenylalanine derivative; secondary carboxamide	cathepsin L (EC 3.4.22.15) inhibitor
win 56291 Win 56291: anti-rhinoviral drug; structure given in first source	2.1	1	0
atazanavir atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).	3.1	1	0	carbohydrazide	antiviral drug; HIV protease inhibitor
bila 2157 bs BILA 2157 BS: renin inhibitor; RN given for (1S-(1R(S),2S,3R))-isomer; structure in first source	3.1	1	0
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	3.41	1	0	abietane diterpenoid
melagatran [no description available]	3.1	1	0	azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor
nutlin 3 [no description available]	3.41	1	0	stilbenoid
1-methylpropyl-2-imidazolyl disulfide 1-methylpropyl-2-imidazolyl disulfide: a thioredoxin inhibitor with antineoplastic activity	4.33	2	0	imidazoles
anisomycin Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.	3.41	1	0	monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic	anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor
homoharringtonine Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.	3.41	1	0	alkaloid ester; enol ether; organic heteropentacyclic compound; tertiary alcohol	anticoronaviral agent; antineoplastic agent; apoptosis inducer; protein synthesis inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	4.07	2	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	3.1	1	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
terconazole terconazole: structure & RN for (cis)-isomer from first source. terconazole : A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-terconazole. It has broad-spectrum antifungal activitiy and is used for the treatment of vaginal yeast infections (Candida).. (2R,4S)-terconazole : A 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine in which positions 2 and 4 of the 1,3-dioxolane moiety have R and S configuration, respectively.	3.41	1	0	1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine
acetylleucyl-leucyl-norleucinal acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.	3.41	1	0	aldehyde; tripeptide	cysteine protease inhibitor
candoxatrilat candoxatrilat: USAN lists candoxatrilat (UK-73,967) with RN 123122-54-3. candoxatrilat : A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarboxylic acid. A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.	3.1	1	0
cgp 38560a [no description available]	3.1	1	0
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	4.07	2	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
prinomastat prinomastat: a diazepine-based hydroxamic acid inhibitor; matrix metalloproteinase (MMP) inhibitor; angiogenesis inhibitor;. prinomastat : A hydroxamic acid that is (3S)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide in which the hydrogen attached to the thiomorpholine nitrogen has been replaced by a [4-(pyridin-4-yloxy)phenyl]sulfonyl group. It is a selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14.	3.1	1	0	aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor
shikonin shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities	3.41	1	0	hydroxy-1,4-naphthoquinone
favipiravir favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.	2.52	2	0	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	3.61	2	0
1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide [no description available]	3.41	1	0	indolecarboxamide	anticoronaviral agent
hirsutanone hirsutanone: from methanolic extract of the aerial parts of Viscum cruciatum (Viscaceae)	3.41	1	0	diarylheptanoid
thiothixene [no description available]	3.41	1	0	N-methylpiperazine	anticoronaviral agent
benztropine Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.	3.41	1	0	diarylmethane
tamoxifen [no description available]	3.41	1	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine [no description available]	3.51	1	0	sulfonic acid derivative	anticoronaviral agent
S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate [no description available]	3.41	1	0	acetylenic compound; furans; organofluorine compound; thioester; triazoles
toremifene Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.	3.41	1	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
mk 0608 7-deaza-2'-C-methyladenosine: an antiviral agent	2.1	1	0
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	3.41	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
N-(4-Butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide [no description available]	3.41	1	0	aromatic amide; furans	anticoronaviral agent
rs-130830 RS-130830: orally-active broad-spectrum matrix metalloproteinase inhibitor	3.1	1	0
thiorphan [no description available]	3.1	1	0
quercetin [no description available]	3.41	1	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
luteolin [no description available]	3.41	1	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
luteolin-7-glucoside luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.13	1	0	beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antioxidant; plant metabolite
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	2.13	1	0	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
amentoflavone [no description available]	3.41	1	0	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite
baicalein [no description available]	3.41	1	0	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	2.13	1	0	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
fisetin [no description available]	2.13	1	0	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
hyperoside quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.	3.51	1	0	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
savinin savinin: a lignan from Pterocarpus santalinus inhibits tumor necrosis factor-alpha production and T cell proliferation; structure in first source. savinin : A lignan that is dihydrofuran-2(3H)-one (gamma-butyrolactone) substituted by a 1,3-benzodioxol-5-ylmethylidene group at position 3 and a 1,3-benzodioxol-5-ylmethyl group at position 4 (the 3E,4R-isomer). It exhibits antiviral activity against SARS-CoV-2.	3.41	1	0	benzodioxoles; gamma-lactone; lignan	anti-inflammatory agent; anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; plant metabolite; T-cell proliferation inhibitor
dothiepin hydrochloride Dothiepin: A tricyclic antidepressant with some tranquilizing action.	3.41	1	0	dothiepin
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.11	1	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
alatriopril alatriopril: shows promise for the treatment of various cardiovascular & salt-retention disorders	3.1	1	0
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	3.1	1	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.	3.1	1	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	3.1	1	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	3.1	1	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	3.1	1	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
cinanserin Cinanserin: A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity.. cinanserin : An aryl sulfide that is (2E)-3-phenyl-N-(2-sulfanylphenyl)prop-2-enamide in which the hydrogen of the thiol group is substituted by a 3-(dimethylamino)propyl group. It is a 5-hydroxytryptamine receptor antagonist and an inhibitor of SARS-CoV replication.	3.41	1	0	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
pepstatin pepstatin: inhibits the aspartic protease endothiapepsin	3.1	1	0	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	3.1	1	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one: a janus-activated kinase inhibitor. 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one : An organic heterotetracyclic compound that is 1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one bearing additional tert-butyl and fluoro substituents at positions 2 and 9 respectively.	3.41	1	0	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
viroxime [no description available]	2.1	1	0
gw-5074 [no description available]	2.13	1	0
N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide : A tripeptide resulting from the formal condensation of the carboxy group of N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valine with the amino group of benzyl (2E,4S)-4-(L-leucylamino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate. It is an inhibitor of the main protease of SARS-CoV-2.	3.51	1	0	benzyl ester; isoxazoles; pyrrolidin-2-ones; tripeptide	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
ro 42-5892 remikiren : An L-histidine derivative that is L-histidine in which one of the amino hydrogens is replaced by a (2S)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl group and the carboxy group is replaced by a [(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino group. It is a renin inhibitor which was under development for the treatment of hypertension (now discontinued).	3.1	1	0	cyclopropanes; diol; L-histidine derivative; secondary carboxamide; sulfone	antihypertensive agent; EC 3.4.23.15 (renin) inhibitor; peptidomimetic; vasodilator agent
broussochalcone a broussochalcone A: RN given for (E)-isomer; inhibits neutrophil respiratory burst; structure in first source	3.41	1	0
Ethyl (E,4S)-4-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-phenylpropanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate [no description available]	3.84	3	0	dipeptide	anticoronaviral agent
napsagatran napsagatran: structure given in first source	3.1	1	0
bay 12-9566 Bay 12-9566: an angiogenesis inhibitor with matrix metalloproteinase inhibitory activity	3.1	1	0	biphenyls; organochlorine compound
5-Chloro-3-pyridinyl 2-furoate [no description available]	3.41	1	0	carboxylic ester	anticoronaviral agent
fosinopril [no description available]	3.1	1	0
ym 60828 YM 60828: YM-466 is the mesylate salt	3.1	1	0
ro 32-3555 Ro 32-3555: structure given in first source	3.1	1	0
carbobenzoxy-leucyl-leucyl-norvalinal carbobenzoxy-leucyl-leucyl-norvalinal: structure given in first source	3.41	1	0	peptide
sja 6017 N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal: structure in first source	3.41	1	0
zd 8321 ZD 8321: inhibits human leukocyte elastase; structure in first source	3.1	1	0
sotrastaurin sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source. sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients.	3.41	1	0	indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines	anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent
saracatinib [no description available]	3.41	1	0	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.	3.41	1	0	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	4.97	4	0
np 031112 tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.	4.33	2	0	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
PF-00835231 PF-00835231 : A primary alcohol resulting from the cleavage of the phosphate group of the prodrug PF-07304814. It is an inhibitor of SARS-CoV-1 and -2 main protease (3CLpro) and exhibits potent in vitro antiviral activity.	3.51	1	0	aromatic ether; indolecarboxamide; L-leucine derivative; primary alcohol; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; drug metabolite; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
narlaprevir narlaprevir: an antiviral agent that inhibits hepatitis C virus NS3 protease. narlaprevir : An azabicyclohexane that is (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane substituted by [(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]aminoacyl and N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl groups at positions 2S and 3, respectively. It is a hepatitis C virus (HCV) NS3/4A serine protease inhibitor (Ki = 6 nM) that is used for the treatment of chronic hepatitis C.	3.41	1	0	azabicyclohexane; cyclopropanes; pyrrolidinecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide; ureas	anticoronaviral agent; antiviral drug; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; hepatitis C protease inhibitor
Benzotriazol-1-yl 1H-indole-5-carboxylate [no description available]	3.41	1	0	indolyl carboxylic acid	anticoronaviral agent
5-Chloropyridin-3-yl 5-(4-chlorophenyl)furan-2-carboxylate [no description available]	3.41	1	0	carboxylic ester	anticoronaviral agent
(5-Chloropyridin-3-yl) 1H-indole-5-carboxylate [no description available]	3.41	1	0	indolyl carboxylic acid	anticoronaviral agent
5-Chloropyridin-3-yl 1H-indole-2-carboxylate [no description available]	3.41	1	0	indolyl carboxylic acid	anticoronaviral agent
GRL-0617 GRL-0617 : A benzamide resulting from the formal condensation of the carboxy group of 5-amino-2-methylbenzoic acid with the amino group of (1R)-1-(naphthalen-1-yl)ethan-1-amine. It is a potent noncovalent inhibitor (IC50 = 600 nM) of severe acute respiratory syndrome-coronavirus papain-like protease (SARS-CoV PLpro).	3.41	1	0	benzamides; naphthalenes; secondary carboxamide; substituted aniline	anticoronaviral agent; protease inhibitor
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate [no description available]	3.41	1	0	indolyl carboxylic acid	anticoronaviral agent
KOM70144 KOM70144 : A benzamide that is GRL-0617 in which one of the hydrogen's of the primary amino group is replaced by an acetyl group. It an inhibitor of SARS-CoV and SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 2.6 muM and 5.0 muM, respectively. It also inhibits SARS-CoV and SARS-CoV-2 infection of Vero E6 cells in vitro (EC50 values are 13.1 and 21 muM, respectively).	3.41	1	0	acetamides; benzamides; naphthalenes; secondary carboxamide	anticoronaviral agent; protease inhibitor
piperidines Piperidines: A family of hexahydropyridines.	2.5	2	0
nitd008 NITD008: inhibits enterovirus 71	2.52	2	0
N-[(1R)-2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide [no description available]	3.41	1	0	aromatic amide; furans
s 8932 [no description available]	3.41	1	0	aromatic amine; C-nucleoside; carboxylic ester; nitrile; phosphoramidate ester; pyrrolotriazine	anticoronaviral agent; antiviral drug; prodrug
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-cyclohexyl-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-alaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.53 muM).	3.41	1	0	aldehyde; indolecarboxamide; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
molnupiravir molnupiravir: prodrug that’s metabolized into N4-hydroxycytidine (NHC), a ribonucleoside analog. molnupiravir : A nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19.	3.41	1	0	isopropyl ester; ketoxime; nucleoside analogue	anticoronaviral agent; antiviral drug; prodrug
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-fluoro-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.72 muM).	3.41	1	0	aldehyde; indolecarboxamide; monofluorobenzenes; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor

Condition	Relationship Strength	Studies	Trials
Catarrh Inflammation of a mucous membrane with increased flow of mucous in humans or animals. Catarrh is used mostly in a historical context.	6.34	5	1
Common Cold A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.	6.34	5	1
Enterovirus Infections Diseases caused by ENTEROVIRUS.	3.47	7	0
Caliciviridae Infections Virus diseases caused by CALICIVIRIDAE. They include HEPATITIS E; VESICULAR EXANTHEMA OF SWINE; acute respiratory infections in felines, rabbit hemorrhagic disease, and some cases of gastroenteritis in humans.	3.5	2	0
Gastroenteritis INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.	8.53	2	0
2019 Novel Coronavirus Disease [description not available]	3.23	1	0
Infections, Picornaviridae [description not available]	4.9	5	0
Airflow Obstruction, Chronic [description not available]	2.31	1	0
Asthma, Bronchial [description not available]	2.31	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.31	1	0
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	2.31	1	0
Hand Foot and Mouth Disease [description not available]	8.94	4	0
Hand, Foot and Mouth Disease A mild, highly infectious viral disease of children, characterized by vesicular lesions in the mouth and on the hands and feet. It is caused by coxsackieviruses A.	8.94	4	0
Respiratory Syndrome, Acute, Severe [description not available]	2.44	2	0
Severe Acute Respiratory Syndrome A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.	2.44	2	0
Infections, RNA Virus [description not available]	2.05	1	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	2.06	1	0

rupintrivir

Description

Cross-References

Synonyms (43)

Research Excerpts

Overview

Toxicity

Dosage Studied

Protein Targets (17)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (90)

Molecular Functions (47)

Ceullar Components (38)

Bioassays (189)

Research

Studies (68)

Market Indicators

Research Demand Index: 31.73

Study Types

rupintrivir

Description

Cross-References

Synonyms (43)

Research Excerpts

Overview

Toxicity

Dosage Studied

Protein Targets (17)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (90)

Molecular Functions (47)

Ceullar Components (38)

Bioassays (189)

Research

Studies (68)

Market Indicators

Research Demand Index: 31.73

Study Types

Related Drugs (166)

Related Conditions (17)